Top

Current Treatment Options in Gastroenterology

Published in:

01-06-2019 | Bacterial Peritonitis | Liver (J Bajaj, Section Editor)

Infections in Cirrhosis

Authors: Sirina Ekpanyapong, MD, K. Rajender Reddy, MD

Published in: Current Treatment Options in Gastroenterology | Issue 2/2019

Abstract

Purpose of review

Patients with cirrhosis are at high risk of developing serious infections. Bacterial infections remain the most common cause of morbidity and mortality in these patients. This review is focused on the prevalence of infections in those with cirrhosis, including multidrug-resistant (MDR) pathogens, pathogenesis of infection-related acute-on-chronic liver failure (ACLF), current treatment recommendations, and prophylactic strategies in patients with cirrhosis.

Recent findings

Recent epidemiological studies have noted an emerging prevalence of MDR bacterial infections and associated with poor prognosis, and a high rate of treatment failure and mortality. Therefore, new recommendations on empirical antibiotic use based on epidemiological data have been developed in order to improve outcomes.

Summary

Spontaneous bacterial peritonitis (SBP) and urinary tract infection (UTI) are the most frequent infections followed by pneumonia, cellulitis, and bacteremia, while pneumonia carries the highest risk of mortality. The incidence of MDR bacterial infections has been increasing, especially in healthcare-associated settings. Second infections that develop during hospitalization, multiple organ failures, and high MELD score are associated with poor survival. Preventive measures, early diagnosis, and adequate treatment of infections are essential key concepts in minimizing morbidity and mortality in patients with cirrhosis.

Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clinical Gastroenterol Hepatol. 2011;9(9):727–38. https://doi.org/10.1016/j.cgh.2011.02.031.CrossRef

Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831–40. https://doi.org/10.1002/hep.21737.CrossRefPubMed

Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol. 2005;42(2):195–201. https://doi.org/10.1016/j.jhep.2004.10.019.CrossRefPubMed

Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310–24. https://doi.org/10.1016/j.jhep.2014.01.024.CrossRefPubMed

Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1–12. https://doi.org/10.1016/S0168-8278(12)60002-6.CrossRefPubMed

Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55(5):1551–61. https://doi.org/10.1002/hep.25532.CrossRefPubMed

Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979–85. https://doi.org/10.1016/j.cgh.2010.06.024.CrossRefPubMed

Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140–8. https://doi.org/10.1053/jhep.2002.30082.CrossRefPubMed

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37,37.e1–9. https://doi.org/10.1053/j.gastro.2013.02.042.CrossRefPubMed

10.

Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45(1):223–9. https://doi.org/10.1002/hep.21443.CrossRefPubMed

11.

Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver Int. 2018;38(Suppl 1):126–33. https://doi.org/10.1111/liv.13645.CrossRefPubMed

12.

Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest. 2003;124(3):1016–20.CrossRef

13.

Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–56,56.e1–5. https://doi.org/10.1053/j.gastro.2010.06.019.CrossRefPubMed

14.

• Fernandez J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology. J Hepatol. 2016;65(5):1043–54. https://doi.org/10.1016/j.jhep.2016.08.006A brief review of treatment strategies and global health crisis of antimicrobial resistance in cirrhosis. CrossRefPubMed

15.

• Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, et al. Epidemiology, predictors and outcomes of multi drug resistant (MDR) bacterial infections in patients with cirrhosis across the world. Final results of the “Global study”. Digestive and Liver Disease. 2018;50(1, supplement):2–3. https://doi.org/10.1016/j.dld.2018.01.007A multicenter study of global prevalence and epidemiology of MDR bacterial infections in cirrhosis. CrossRef

16.

Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–96. https://doi.org/10.1016/j.jhep.2014.08.010.CrossRefPubMed

17.

Bunchorntavakul C, Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol. 2012;4(5):158–68. https://doi.org/10.4254/wjh.v4.i5.158.CrossRefPubMedPubMedCentral

18.

Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol. 2017;30(5):486–97. https://doi.org/10.20524/aog.2017.0178.CrossRefPubMedPubMedCentral

19.

Bellot P, Garcia-Pagan JC, Frances R, Abraldes JG, Navasa M, Perez-Mateo M, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):2044–52. https://doi.org/10.1002/hep.23918.CrossRefPubMed

20.

Sadik R, Abrahamsson H, Bjornsson E, Gunnarsdottir A, Stotzer PO. Etiology of portal hypertension may influence gastrointestinal transit. Scand J Gastroenterol. 2003;38(10):1039–44.CrossRef

21.

Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–21. https://doi.org/10.1016/j.jhep.2012.12.011.CrossRefPubMed

22.

Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18(5):1139–43.CrossRef

23.

Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;17:756–765.e3. https://doi.org/10.1016/j.cgh.2018.07.022.CrossRefPubMed

24.

Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Investig. 2012;42(4):439–46. https://doi.org/10.1111/j.1365-2362.2011.02609.x.CrossRef

25.

Saitoh O, Sugi K, Lojima K, Matsumoto H, Nakagawa K, Kayazawa M, et al. Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol. 1999;5(5):391–6.CrossRef

26.

Lorenzo-Zuniga V, Bartoli R, Planas R, Hofmann AF, Vinado B, Hagey LR, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37(3):551–7. https://doi.org/10.1053/jhep.2003.50116.CrossRefPubMed

27.

Teltschik Z, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology. 2012;55(4):1154–63. https://doi.org/10.1002/hep.24789.CrossRefPubMed

28.

Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol. 2014;20(10):2542–54. https://doi.org/10.3748/wjg.v20.i10.2542.CrossRefPubMedPubMedCentral

29.

Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis. 2016;36(2):109–16. https://doi.org/10.1055/s-0036-1583202.CrossRefPubMed

30.

Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–53. https://doi.org/10.1136/gutjnl-2016-312670.CrossRefPubMedPubMedCentral

31.

O'Leary JG, Reddy KR, Garcia-Tsao G, Biggins SW, Wong F, Fallon MB, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology. 2018;67(6):2367–74. https://doi.org/10.1002/hep.29773.CrossRefPubMed

32.

•• Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60(1):250–6. https://doi.org/10.1002/hep.27077The study using NACSELD database on prevalence and survival of infection-related ACLF in hospitalized cirrhotic patients. CrossRefPubMedPubMedCentral

33.

• Reddy KR, O’Leary JG, Kamath PS, Fallon MB, Biggins SW, Wong F, et al. High risk of delisting or death in liver transplant candidates following infections: results from the North American Consortium for the Study of End-Stage Liver Disease. Liver Transpl. 2015;21(7):881–8. https://doi.org/10.1002/lt.24139The study using NACSELD database on prognosis of liver transplant candidates following infections. CrossRef

34.

Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology. 2003;37(4):897–901. https://doi.org/10.1053/jhep.2003.50119.CrossRefPubMed

35.

Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142–53.CrossRef

36.

Chinnock B, Afarian H, Minnigan H, Butler J, Hendey GW. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. Ann Emerg Med. 2008;52(3):268–73. https://doi.org/10.1016/j.annemergmed.2008.02.016.CrossRefPubMed

37.

•• EASL. Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60. https://doi.org/10.1016/j.jhep.2018.03.024An updated EASL guideline and recommendations 2018 for bacterial infections in cirrhosis including both SBP and non-SBP infections. CrossRef

38.

Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012;61(2):297–310. https://doi.org/10.1136/gutjnl-2011-300779.CrossRefPubMed

39.

Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107. https://doi.org/10.1002/hep.22853.CrossRefPubMed

40.

Nousbaum JB, Cadranel JF, Nahon P, Khac EN, Moreau R, Thevenot T, et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology. 2007;45(5):1275–81. https://doi.org/10.1002/hep.21588.CrossRefPubMed

41.

Parsi MA, Saadeh SN, Zein NN, Davis GL, Lopez R, Boone J, et al. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology. 2008;135(3):803–7. https://doi.org/10.1053/j.gastro.2008.05.045.CrossRefPubMed

42.

Lee SS, Min HJ, Choi JY, Cho HC, Kim JJ, Lee JM, et al. Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis. BMC Gastroenterol. 2016;16(1):132. https://doi.org/10.1186/s12876-016-0546-9.CrossRefPubMedPubMedCentral

43.

Enomoto H, Inoue S, Matsuhisa A, Aizawa N, Imanishi H, Saito M, et al. Development of a new in situ hybridization method for the detection of global bacterial DNA to provide early evidence of a bacterial infection in spontaneous bacterial peritonitis. J Hepatol. 2012;56(1):85–94. https://doi.org/10.1016/j.jhep.2011.06.025.CrossRefPubMed

44.

Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–3. https://doi.org/10.1002/hep.26359.CrossRefPubMed

45.

Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150(1):19–26.CrossRef

46.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.CrossRefPubMed

47.

Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–9. https://doi.org/10.1056/NEJM199908053410603.CrossRef

48.

•• Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–21. https://doi.org/10.4254/wjh.v8.i6.307A detailed review of bacterial infections in cirrhosis. CrossRefPubMedPubMedCentral

49.

Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Weekly Rep. 2015;64(34):944–7. https://doi.org/10.15585/mmwr.mm6434a4.CrossRef

50.

Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(Rr-16):1–33quiz CE1–4.PubMed

51.

Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1994;20(1 Pt 1):34–8.CrossRef

52.

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther. 2011;34(5):509–18. https://doi.org/10.1111/j.1365-2036.2011.04746.x.CrossRefPubMed

53.

Fernandez J, Ruiz del Arbol L, Gomez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049–56;quiz 1285. https://doi.org/10.1053/j.gastro.2006.07.010.CrossRefPubMed

54.

Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818–24. https://doi.org/10.1053/j.gastro.2007.06.065.CrossRefPubMed

55.

Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol. 2008;48(5):774–9. https://doi.org/10.1016/j.jhep.2008.01.024.CrossRefPubMed

56.

Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716–24.CrossRef

57.

Navasa M, Rimola A, Rodes J. Bacterial infections in liver disease. Semin Liver Dis. 1997;17(4):323–33. https://doi.org/10.1055/s-2007-1007209.CrossRefPubMed

58.

Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut. 1984;25(2):133–7.CrossRef

59.

Cruz Rde C, Tanajura D, Almeida D, Cruz M, Parana R. Urinary tract infection in non-hospitalized patients with cirrhosis and no symptoms of urinary tract infection: a case series study. Braz J Infect Dis. 2006;10(6):380–3.PubMed

60.

Bjerklund Johansen TE, Cek M, Naber K, Stratchounski L, Svendsen MV, Tenke P. Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol. 2007;51(4):1100–11;discussion 12. https://doi.org/10.1016/j.eururo.2006.08.012.CrossRefPubMed

61.

Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin Microbiol Infect. 2001;7(10):532–42.CrossRef

62.

Jimenez-Alcaide E, Medina-Polo J, Garcia-Gonzalez L, Arrebola-Pajares A, Guerrero-Ramos F, Perez-Cadavid S, et al. Healthcare-associated urinary tract infections in patients with a urinary catheter: risk factors, microbiological characteristics and patterns of antibiotic resistance. Arch Esp Urol. 2015;68(6):541–50.PubMed

63.

Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents. 2008;31(Suppl 1):S68–78. https://doi.org/10.1016/j.ijantimicag.2007.07.033.CrossRefPubMed

64.

Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14. https://doi.org/10.1086/668770.CrossRefPubMed

65.

Chitnis AS, Edwards JR, Ricks PM, Sievert DM, Fridkin SK, Gould CV. Device-associated infection rates, device utilization, and antimicrobial resistance in long-term acute care hospitals reporting to the National Healthcare Safety Network, 2010. Infect Control Hosp Epidemiol. 2012;33(10):993–1000. https://doi.org/10.1086/667745.CrossRefPubMed

66.

Hung TH, Tseng CW, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol. 2013;13:25. https://doi.org/10.1186/1471-230X-13-25.CrossRefPubMedPubMedCentral

67.

Viasus D, Garcia-Vidal C, Castellote J, Adamuz J, Verdaguer R, Dorca J, et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine. 2011;90(2):110–8. https://doi.org/10.1097/MD.0b013e318210504c.CrossRefPubMed

68.

Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007;41(4):403–11. https://doi.org/10.1097/01.mcg.0000248018.08515.f9.CrossRefPubMed

69.

Hamza RE, Villyoth MP, Peter G, Joseph D, Govindaraju C, Tank DC, et al. Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence. Ann Gastroenterol. 2014;27(4):374–9.PubMedPubMedCentral

70.

Lee CC, Chi CH, Lee NY, Lee HC, Chen CL, Chen PL, et al. Necrotizing fasciitis in patients with liver cirrhosis: predominance of monomicrobial Gram-negative bacillary infections. Diagn Microbiol Infect Dis. 2008;62(2):219–25. https://doi.org/10.1016/j.diagmicrobio.2008.05.016.CrossRefPubMed

71.

Acevedo JG, Fernandez J, Castro M, Garcia O, de Lope CR, Navasa M, et al. 6 current efficacy of recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection. J Hepatol. 2009;50:S5. https://doi.org/10.1016/S0168-8278(09)60008-8.CrossRef

72.

Lahmer T, Messer M, Mayr U, Saugel B, Noe S, Schultheiss C, et al. Fungal “colonisation” is associated with increased mortality in medical intensive care unit patients with liver cirrhosis. Mycopathologia. 2015;179(1–2):63–71. https://doi.org/10.1007/s11046-014-9825-6.CrossRefPubMed

73.

Lahmer T, Messer M, Schwerdtfeger C, Rasch S, Lee M, Saugel B, et al. Invasive mycosis in medical intensive care unit patients with severe alcoholic hepatitis. Mycopathologia. 2014;177(3–4):193–7. https://doi.org/10.1007/s11046-014-9740-x.CrossRefPubMed

74.

Alexopoulou A, Vasilieva L, Agiasotelli D, Dourakis SP. Fungal infections in patients with cirrhosis. J Hepatol. 2015;63(4):1043–5. https://doi.org/10.1016/j.jhep.2015.05.032.CrossRefPubMed

75.

Bajaj JS, Rajender Reddy K, Tandon P, Wong F, Kamath PS, Biggins SW, et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am J Gastroenterol. 2018;113(4):556–63. https://doi.org/10.1038/ajg.2017.471.CrossRefPubMed

76.

Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–28. https://doi.org/10.1056/NEJMoa1412278.CrossRefPubMed

77.

Hmoud BS, Patel K, Bataller R, Singal AK. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver Int. 2016;36(5):721–8. https://doi.org/10.1111/liv.12939.CrossRefPubMed

78.

Gustot T, Maillart E, Bocci M, Surin R, Trepo E, Degre D, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol. 2014;60(2):267–74. https://doi.org/10.1016/j.jhep.2013.09.011.CrossRefPubMed

79.

Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep. 2013;15(1):300. https://doi.org/10.1007/s11894-012-0300-6.CrossRefPubMed

80.

Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine. 2003;21(19–20):2238–41.CrossRef

81.

Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med. 2005;118(Suppl 10A):21s–7s. https://doi.org/10.1016/j.amjmed.2005.07.013.CrossRefPubMed

82.

Smallwood GA, Coloura CT, Martinez E, Stieber AC, Heffron TG. Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine? Transplant Proc. 2002;34(8):3289–90.CrossRef

83.

Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology. 2001;34(1):28–31. https://doi.org/10.1053/jhep.2001.25883.CrossRefPubMed

84.

Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999;94(6):1601–4. https://doi.org/10.1111/j.1572-0241.1999.01150.x.CrossRefPubMed

85.

Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur RS. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;2013:196704–5. https://doi.org/10.1155/2013/196704.CrossRefPubMedPubMedCentral

86.

Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver Transpl Surg. 1998;4(5):437–9.CrossRef

87.

Chlabicz S, Grzeszczuk A. Hepatitis B virus vaccine for patients with hepatitis C virus infection. Infection. 2000;28(6):341–5.CrossRef

88.

Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis. 2008;12(4):306–9.CrossRef

89.

Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318(5):304–7.CrossRef

90.

Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol. 1990;85(12):1590–2.PubMed

91.

Mendenhall C, Roselle GA, Lybecker LA, Marshall LE, Grossman CJ, Myre SA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. Dig Dis Sci. 1988;33(3):263–9.CrossRef

92.

Waghray A, Waghray N, Khallafi H, Menon KV. Vaccinating adult patients with cirrhosis: trends over a decade in the United States. Gastroenterol Res Pract. 2016;2016:5795712–7. https://doi.org/10.1155/2016/5795712.CrossRefPubMedPubMedCentral

Title: Infections in Cirrhosis
Authors: Sirina Ekpanyapong, MD
K. Rajender Reddy, MD
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Bacterial Peritonitis
Vaccination
Antibiotic
Pneumonia
Norfloxacin
Urinary Tract Infection
Published in: Current Treatment Options in Gastroenterology / Issue 2/2019
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-019-00229-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2019

Endoscopic Papillary Large Balloon Dilation Versus Endoscopic Sphincterotomy for Treatment of Bile Duct Stones

2007–2019: a “Third”-Space Odyssey in the Endoscopic Management of Gastrointestinal Tract Diseases

Durability of Endoscopic Treatment for Dysplastic Barrett’s Esophagus

Contemporary Epidemiology of Cirrhosis

Colorectal Cancer Screening and Surveillance Colonoscopy in Older Adults

Albumin in Cirrhosis: More Than a Colloid

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage